Longitudinal Study to Find the Association of Serum Phosphorus Level with FGF23 in Three Different Hyperphosphatemia Management Groups of Stage 3 and 4 Chronic Kidney Disease (CKD) Patients

Overview

Journal Indian J Nephrol

Specialty Nephrology

Date 2023 Jan 27

PMID 36704588

Authors

Himansu Sekhar Mahapatra

Navjot Kaur

Neera Sharma

Lalit Pursnani

Muthu Kumar

Neeraj Inamdar

Mansi Singh

Tannu Arora

Affiliations

Soon will be listed here.

Abstract

Background: There is paucity of clinical evidence on target serum phosphorus levels in early chronic kidney disease (CKD). Present longitudinal study was done to find target phosphorus level and its association with fibroblast growth factor (FGF23) in three different hyperphosphatemia management groups.

Methods: This 1-year, prospective, randomized controlled, open-labelled study was conducted among three equally allocated treatment groups that consisted of 120 screened early CKD patients totally. Group 1 patients were given dietary phosphorus modification ( = 40), group 2 patients were administered calcium-based phosphate binders ( = 40), and group 3 patients were given non-calcium-based phosphate binders ( = 40). Three-monthly dietary assessment, MDRD estimated glomerular filtration rate (eGFR), phosphorus, calcium, iPTH, alkaline phosphatase, and six-monthly FGF23, 2D echocardiography, and X-ray of chest and abdomen were performed. Association of three categories of phosphorus level up to 3.9, 4-5, and >5mg/dl, rate of progression of all parameters, and correlation with FGF23 were studied among all three groups.

Results: At baseline, all clinical and biochemical parameters were equally distributed with a controlled nutritional phosphate among all groups. There was no significant difference of FGF23 levels from all the three categories of phosphorus level among all groups. Serum phosphorus at the level of 5 mg/dl was associated with iPTH and eGFR at 1 year. Over 1 year, there was a significant decline in serum phosphorus levels in group 1 ( 0.02), group 2 ( 0.00), and group 3 ( 0.05). FGF23 declined significantly only in group 3 ( 0.00). There was no correlation of FGF23 with serum phosphorus levels ( 0.13). However, FGF23 correlated positively with iPTH ( 0.03, = 0.19).

Conclusion: Serum phosphorus levels upto 5mg/dl had no effect on FGF23 at early CKD stages. Although different treatment groups showed significant phosphorus reduction, non-calcium phosphate binder had a major impact on FGF23 reduction.

Citing Articles

Longitudinal Assessment of Health-Related Quality of Life in Three Different Hyperphosphatemia Management Groups of Stage III and IV Chronic Kidney Disease Patients.

Kaur N, Mahapatra H, Pursnani L, B M, Singh M, Gupta Y Indian J Nephrol. 2024; 34(2):119-128.

PMID: 38681013 PMC: 11044664. DOI: 10.4103/ijn.ijn_6_23.

References

Isakova T, Gutierrez O, Smith K, Epstein M, Keating L, Juppner H . Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2010; 26(2):584-91. PMC: 3108359. DOI: 10.1093/ndt/gfq419. View

Chang A, Anderson C . Dietary Phosphorus Intake and the Kidney. Annu Rev Nutr. 2017; 37:321-346. PMC: 5686387. DOI: 10.1146/annurev-nutr-071816-064607. View

Liabeuf S, Ryckelynck J, El Esper N, Urena P, Combe C, Dussol B . Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. Clin J Am Soc Nephrol. 2017; 12(12):1930-1940. PMC: 5718266. DOI: 10.2215/CJN.03030317. View

Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley R . Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5(12):2251-7. PMC: 2994087. DOI: 10.2215/CJN.00810110. View

. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225):709-733. PMC: 7049905. DOI: 10.1016/S0140-6736(20)30045-3. View

Mitchell D, Juppner H, Burnett-Bowie S . FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab. 2017; 102(4):1151-1160. PMC: 5460726. DOI: 10.1210/jc.2016-4038. View

Vervloet M, van Ittersum F, Buttler R, Heijboer A, Blankenstein M, Ter Wee P . Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. 2010; 6(2):383-9. PMC: 3052230. DOI: 10.2215/CJN.04730510. View

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1):26-36. DOI: 10.1016/j.kint.2017.04.006. View

Wolf M . Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82(7):737-47. PMC: 3434320. DOI: 10.1038/ki.2012.176. View

10.

Ketteler M . Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control. Int J Nephrol. 2011; 2011:970245. PMC: 3108253. DOI: 10.4061/2011/970245. View

11.

Kuro-O M . A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech Ageing Dev. 2010; 131(4):270-5. PMC: 2862786. DOI: 10.1016/j.mad.2010.02.008. View

12.

Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H . Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol. 2014; 15:71. PMC: 4107721. DOI: 10.1186/1471-2369-15-71. View

13.

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

14.

Fliser D, Kollerits B, Neyer U, Ankerst D, Lhotta K, Lingenhel A . Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9):2600-8. DOI: 10.1681/ASN.2006080936. View

15.

Bleskestad I, Bergrem H, Hartmann A, Godang K, Goransson L . Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol. 2012; 13:49. PMC: 3462711. DOI: 10.1186/1471-2369-13-49. View

16.

Yaghoubi F, Ahmadi F, Lesanpezeshki M, Mahdavi Mazde M . A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis. J Renal Inj Prev. 2016; 5(2):104-7. PMC: 4962669. DOI: 10.15171/jrip.2016.22. View

17.

Cancela A, Oliveira R, Graciolli F, Dos Reis L, Barreto F, Barreto D . Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2010; 117(1):c74-82. DOI: 10.1159/000319650. View

18.

Block G, Wheeler D, Persky M, Kestenbaum B, Ketteler M, Spiegel D . Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23(8):1407-15. PMC: 3402292. DOI: 10.1681/ASN.2012030223. View

19.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

20.

Tsai W, Wu H, Peng Y, Hsu S, Chiu Y, Yang J . Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial. Clin J Am Soc Nephrol. 2019; 14(10):1475-1483. PMC: 6777602. DOI: 10.2215/CJN.04250419. View